日期: 2026年4月13日

HONG KONG, Apr 13, 2026 - (ACN Newswire via SeaPRwire.com) - JS Global Lifestyle Company Limited (Stock Code: 1691.HK) ("JS Global" or the "Company") has announced its annual results for 2025 – a period in which it has demonstrated a strong recovery in core operations. Although reported profit was affected by non-recurring items, adjusted net profit surged 338.0% year-on-year to US$31.0 million, significantly exceeding market expectations and marking a clear inflection point in the Company's profit recovery.In 2025, the Company's total revenue reached US$1.66 billion, representing a year-on-year increase of 4.1%. Gross profit margin improved by 0.2 percentage points to 32.2%, reflecting ongoing optimization of product mix and operational efficiency. Revenue from third parties grew 14.8% year-on-year to US$1.565 billion, with both business segments delivering strong performance: the Joyoung segment saw third-party revenue stabilize and recover, with profit improvement accelerating; the SharkNinja APAC segment recorded third-party revenue of US$533 million, up 55.6% year-on-year, and continued serving as the Company's core growth engine. Within this segment, revenue in Australia and New Zealand grew 73.2% year-on-year to US$255 million, driven notably by new product categories such as ice-cream makers, frozen drink makers and coffee machines. Revenue in Japan increased 41.2% year-on-year to US$158 million, supported by the strong sales performance of key products, including lightweight cordless vacuum cleaners and smart blenders. Both regions benefited from the Company's ongoing new product launches and enhanced brand recognition, with the expansion strategy continuing to deliver favorable results.The Company has stated that, excluding the impact of one-off or non-operating items, operating profit has already improved substantially. With further optimization of selling and administrative expense ratios, the Company's earnings resilience is expected to be bolstered further in 2026.Several financial institutions have issued research notes highlighting JS Global’s currently positive trajectory, the consequence of "Joyoung profit recovery + SharkNinja APAC scale expansion". Huatai Securities maintains a "Buy" rating with a target price of HK$2.38, while Guotai Haitong Securities has assigned an "Overweight" rating, expressing confidence in the Company's medium-term profit resilience. The Company's management has affirmed its commitment to continue driving product innovation and global market expansion, and delivering sustainable growth value to shareholders. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月13日 - (亚太商讯 via SeaPRwire.com) - JS环球生活有限公司（「JS环球生活」或「公司」）（股份编号：1691.HK）发布2025年全年业绩，核心经营层面呈现强劲修复势头。尽管报表利润受非经常性项目扰动，但经调整凈利润同比飙升338.0%至3,100万美元，显著超越市场预期，标志着公司盈利修复拐点已至。2025年，公司实现营业总收入16.60亿美元，同比增长4.1%；毛利率提升0.2个百分点至32.2%，产品结构与经营效率持续优化。公司第三方收入同比增长14.8%至15.65亿美元，两大业务板块表现亮眼：九阳分部第三方收入企稳回升，盈利改善逻辑加速兑现；SharkNinja亚太分部第三方收入同比高增55.6%至5.33亿美元，继续担当公司增长核心引擎，其中澳新市场收入同比增长73.2%至2.55亿美元，冰淇淋机、冷饮机及咖啡机等新品类增长尤为突出，日本市场收入同比增长41.2%至1.58亿美元，轻量化无绳吸尘器、智能搅拌机等优势产品表现强劲，两大区域均受益于公司持续的新品投放与品牌认知提升，扩张策略持续兑现。公司表示，剔除一次性或非经营性项目影响，公司经营利润已实现实质性改善。随着管理和销售费用率优化，公司盈利弹性有望在2026年进一步释放。多家机构发布点评指出，JS环球生活当前正处于「九阳利润修复+SharkNinja亚太规模扩张」的良性通道。华泰证券维持「买入」评级，目标价2.38港元；国泰海通给予「增持」评级，看好公司中期利润弹性。公司管理层表示，将持续推进产品创新与全球市场拓展，致力于为股东创造可持续增长价值。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 13, 2026 - (ACN Newswire via SeaPRwire.com) - This article serves as a foundational study for the Noah Medical deep-dive series, aiming to help investors establish a core framework for assessing value in the medical robotics industry.As the medical robotics sector continues to gain momentum, market discussion tends to center on technical specifications and commercialization progress. Yet from a long-term investment perspective, these dimensions alone cannot explain the divergence in value among companies. What truly determines a medical robotics company's long-term worth is not the technology itself—but the level of clinical problem it solves.The global medical robotics market is projected to grow from roughly USD 70–80 billion in 2023 to over USD 200 billion by around 2030, representing a compound annual growth rate above 15%. More notable, however, is the structural shift underway: the industry's core growth driver is moving rapidly from the "surgical execution end" toward the "diagnostic gateway"—that is, earlier disease detection and more accurate early-stage diagnosis and intervention. Competition around device performance is giving way to competition around solving clinical problems themselves.I. A Three-Tier Value Framework: Problem Level Determines Long-Term UpsideAt its core, medical innovation addresses clinical problems that can be organized into three progressive tiers:- Tier 1: Can it be done at all? — Procedures that were previously infeasible or unreliable, representing breakthroughs in clinical capability.- Tier 2: Can it be done faster? — Corresponding to efficiency gains.- Tier 3: Can it be done more affordably? — Corresponding to cost optimization.Most medical robotics innovation today remains concentrated in the latter two tiers—essentially extending existing clinical capabilities. The truly scarce and defensible direction is Tier 1: using technology to make previously unachievable medical procedures safe and accurate, thereby creating breakthrough clinical value.This logic has been validated repeatedly. The da Vinci Surgical System, with a global installed base exceeding 8,000 units and over 2 million annual procedures, owes its sustained high gross margins and steady growth to one thing: its irreplaceable ability to enable complex minimally invasive surgeries that could not otherwise be performed. The same principle applies to TAVR and electrophysiology ablation—each opened new markets by establishing entirely new clinical capabilities.Companies that solve "can it be done at all" typically enjoy higher technological barriers, stronger pricing power, longer product lifecycles, and more pronounced valuation premiums.II. An Overlooked Capability Gap: From Detection to DiagnosisThis framework is particularly clear in lung cancer care. Lung cancer remains one of the most prevalent and lethal malignancies worldwide, with over 2.2 million new cases and nearly 1.8 million deaths annually—accounting for more than 18% of all cancer-related mortality.In recent years, the widespread adoption of low-dose CT screening (LDCT) has dramatically improved our ability to detect problems, with pulmonary nodule detection rates reaching 20–30% among high-risk populations. Diagnostic capability, however, has not kept pace—and has instead become a new systemic bottleneck.Consider the challenge of peripheral lung nodules: over 65% of pulmonary nodules are located in the lung periphery, where conventional bronchoscopes face clear limitations in reaching deep-seated lesions. Compounding this, dynamic discrepancies between preoperative CT imaging and the patient's actual respiratory state introduce widespread localization errors in clinical practice.This is not an efficiency problem. It is a capability that has yet to be established. How to reliably access targets within complex pulmonary anatomy, and how to achieve precise localization in a dynamically shifting environment—these capabilities directly determine diagnostic accuracy and safety. They represent a textbook "capability-gap opportunity."For investors, such opportunities share distinct hallmarks: well-defined demand, clear pain points, and high technological barriers. Once a breakthrough is achieved, it typically produces durable competitive moats and extended growth cycles.III. Noah Medical: A Strategic Entry Through the Capability GapAs the industry migrates from "efficiency optimization" to "capability creation," Noah Medical has chosen to enter precisely through the capability gap described above—targeting the core challenge of the confirmatory diagnosis stage in early lung cancer detection, and using technology to enhance lesion access and localization, completing a critical missing link in the diagnostic chain.The technological foundation of this approach lies in the deep integration of real-time image-based localization, AI, and robotic control systems. The Galaxy system dynamically corrects discrepancies between imaging and the patient's anatomy during the procedure, delivering higher-precision lesion localization in complex environments. This is the single most critical technical challenge in diagnosing peripheral lung nodules today.Core Clinical DataSince receiving FDA clearance in 2023, the Galaxy system has been used in over 10,000 clinical procedures across an installed base of more than 50 systems. Robotic navigational bronchoscopy diagnostic yield exceeds 90–93%, with a lesion localization success rate of approximately 96% and a low complication rate, demonstrating a strong safety profile. In the robotic bronchoscopy segment for pulmonary applications, Galaxy holds roughly 5% market share and remains in a phase of rapid growth.From a market standpoint, the global natural orifice surgical robotics market is expected to surpass USD 80 billion, with the lung cancer biopsy sub-segment alone representing approximately USD 6 billion. China's surgical robotics market is projected to sustain a 30–36% compound annual growth rate over the coming years, with select early-stage innovative sub-segments growing even faster. More critically, the shift toward non-invasive approaches is continuously expanding the addressable patient population—patients previously excluded due to procedural risk or diagnostic difficulty are steadily entering the diagnosable and treatable pool.The core value of Noah Medical's chosen path lies in combining assured demand with room for expansion: on one hand, lung cancer diagnosis and treatment represents a large and steadily growing base of inelastic clinical need; on the other, the precision access and localization capabilities built on the natural orifice approach carry platform potential for replication across other specialties.Noah Medical is not positioned in a single-product niche. It sits along a capability pathway with the potential for progressive, multi-specialty expansion.ConclusionThe investment logic of medical robotics ultimately comes down to a judgment about problem hierarchy. Amid similar levels of technological excitement and market narrative, the companies that choose to tackle clinical problems not yet effectively solved—and that create new medical capabilities through technology—are the ones most likely to deliver true long-term structural value.Noah Medical is a representative company worthy of sustained attention within this framework. Subsequent articles in this series will further examine its technology pathway, clinical evidence, and commercialization trajectory.— This is the first article in the Noah Medical deep-dive research series Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月13日 - (亚太商讯 via SeaPRwire.com) - 本文系 Noah Medical 系列深度报告的铺垫性研究，旨在帮助投资者建立医疗机器人行业的核心价值判断框架在医疗机器人赛道持续升温的当下，市场的讨论往往聚焦于技术参数与商业化进展。然而，从长期投资视角来看，这些维度并不足以解释企业之间的价值分化。真正决定一家医疗机器人公司长期价值的，是其所解决的临床问题的层级--而非技术本身。全球医疗机器人市场规模预计从2023年约700至800亿美元，增长至2030年前后的2000亿美元以上，年复合增速超过15%。更值得关注的是结构性变化：行业的核心增量正加速从"手术执行端"转移至"诊疗入口端"，即更早发现疾病、更准确完成早期诊断与介入。围绕设备性能的竞争，正在让位于围绕"解决临床问题本身"的竞争。一、三层价值逻辑：问题层级决定长期空间拆解医疗创新的本质，临床问题可分为三个递进层级：第一层：能不能做--原本难以实现或稳定性不足的医疗行为，对应临床能力的突破；第二层：做得快不快--对应效率提升；第三层：做得便不便宜--对应成本优化。当前大多数医疗机器人公司的创新仍集中于后两个层级，本质是对既有医疗能力的延伸。真正稀缺且具备长期壁垒的方向，是切入第一层--通过技术手段，使原本难以完成的医疗行为能够被安全、准确地实现，从而创造突破性的临床价值。这一逻辑已被行业反复验证。达芬奇手术系统全球装机量超过8000台、年手术量超过200万例，其长期高毛利率与稳定增长，核心源于其在复杂微创手术中无可替代的"能力替代性"。TAVR、电生理消融等技术同理--均是通过建立新的临床能力开辟新的市场空间。解决"能不能做"的公司，通常具备更高的技术门槛、更强的定价能力、更长的产品生命周期，以及更显著的估值溢价。二、被忽视的临床能力缺口：从"发现"到"确诊"这一框架，在肺癌诊疗领域尤为清晰。肺癌是全球发病率与死亡率最高的恶性肿瘤之一，每年新增病例超过220万，死亡人数接近180万，占全部癌症死亡的18%以上。近年来，低剂量CT筛查（LDCT）的普及显著提升了"发现问题"的能力--高风险人群中肺结节检出率可达20%至30%。然而，确诊能力并未同步提升，反而成为新的系统性瓶颈。在肺外周结节场景中，超过65%的肺结节位于肺外周区域，传统支气管镜触达深部病灶的成功率存在明显局限。同时，术前CT影像与患者实际呼吸状态之间的动态差异，导致定位误差在临床实践中普遍存在。这不是效率问题，而是能力尚未建立的问题。如何在复杂肺部结构中实现稳定触达、如何在动态环境中完成精准定位--这些核心能力直接决定诊断准确性与安全性，构成典型的"能力缺口型机会"。对投资者而言，这类机会具有明显特征：需求确定、痛点清晰、技术门槛高，一旦突破，往往形成持久壁垒与更长的增长周期。三、Noah Medical：切入能力缺口的战略选择在行业从"效率优化"向"能力创造"迁移的过程中，Noah Medical选择从上述能力缺口切入，聚焦于肺癌早诊过程中确诊环节的核心问题，通过技术手段提升病灶触达与定位能力，补齐诊断链条的关键一环。这一路径的技术基础，在于影像实时定位、AI与机器人控制系统的深度融合。Galaxy系统能够在手术过程中动态修正影像与人体之间的偏差，实现复杂环境下更高精度的病灶定位--这正是当前肺外周结节诊断中最关键的技术难点。核心临床数据Galaxy系统自2023年获FDA批准以来，已累计完成超过10,000例临床手术，装机量超过50台；机器人导航支气管镜诊断率可达90%至93%以上，病灶定位成功率约96%，并发症发生率低，安全性表现良好。在同类肺部机器人支气管镜领域，市场份额约5%，仍处于高速增长阶段。从市场空间来看，全球自然腔道手术机器人市场规模预计超过800亿美元，其中肺癌活检细分市场约60亿美元。中国手术机器人市场预计未来数年保持30%至36%的复合增长率，而部分早期创新细分赛道增速更高。更关键的是，无创化技术路径正在持续扩大潜在诊疗人群--原本因创伤风险或诊疗难度被排除在外的患者，正逐步进入可诊断与可治疗范围。Noah Medical所选择路径的核心价值，在于兼具"确定性需求"与"扩展性空间"：一方面，肺癌诊疗对应庞大且持续增长的刚性临床需求；另一方面，基于自然腔道路径所建立的精准触达与定位能力，具备向其他科室复制拓展的平台潜力。Noah Medical所处的，并非单点产品赛道，而是一条有望逐步延伸的能力路径。结语医疗机器人行业的投资逻辑，本质是一场"问题层级"的判断。在同样的技术热度与市场叙事之下，那些选择切入尚未被有效解决的临床问题、并通过技术创造新增医疗能力的企业，往往才是真正具备长期结构性价值的投资标的。Noah Medical正是在这一框架下值得持续关注的代表性公司。后续系列文章，将进一步拆解其技术路径、临床数据与商业化进展。- 本文为 Noah Medical 系列深度研究第一篇 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com